WEBCAST
FAQ
MEDIA CENTRE
SITE MAP
CONTACT US
CD-ROM
Back to the PAG
Presentation type
Track
Abstract category
Text
All
Oral abstracts
Poster Discussions
Poster Exhibition
CD-ROM
All
A
B
C
D
All
Acute and early infection
Acute and early infection and management of patients with acquired viral resistance
Adherence in adults
Adherence in children and adolescents
Ageing
AIDS related malignancies (KS, lymphoma, cervical and anal carcinoma) including HHV8 infection
Animal Models
Animal models of transmission, disease resistance and progression
Antibody based vaccines
Antiretroviral Therapies (strategic categories apply to resource rich and constrained settings) in Children and Adolescents
Antiretroviral therapy,clinical trials and cohorts
Antiretroviral treatment of people living with HIV for prevention
Approaches to counselling and testing in children and caregivers
Behavioural surveillance
Bioinformatic analysis in drug resistance
Bioinformatics analysis of viral diversity in natural history
Blood, organ and tissue safety and nosocomial transmission
Cellular immunity based vaccines
Clinical trials
Cohort studies
Complementary and traditional medicines and the role of traditional healers in therapy
Complications of Anti-Retroviral Therapy and Adherence in Adults and Children
Correlates of immune protection
Diagnosis of HIV disease
Diagnostic Tools for the Immunological and Virological Monitoring of HIV Infection
Disease burden – morbidity/mortality
Epidemiology of HIV in people who use drugs
Epidemiology of sexually transmitted infections (STI) and HIV
Estimating the need for HIV treatment
Estimating the size of HIV-infected and most at risk population
Ethical issues in epidemiological research
First line therapy
Harm reduction, including reduction of unsafe injecting and other approaches
Hepatitis co-infections: (including HBV, HCV)
HIV counselling, testing and diagnostic strategies
HIV diversity and epidemiology
HIV Pathogenesis/Immune Function and Dysfunction
HIV Pathogenesis/Latency and Viral Reservoirs
HIV superinfections
HIV Surveillance, Monitoring and Evaluation
HIV tropism, dynamics and fitness
HIV-1 and HIV-2 co-infections
HIV-2
Host genetics of resistance and susceptibility
Immune reconstitution disorders / IRIS
Impact of nutrition
Innate immunity responses and function in natural history of HIV infection
Malaria
Male and female condoms and other physical barriers
Male circumcision
Management of late presenters
Measuring and modelling the effect and impact of other HIV prevention interventions
Measuring and modelling the effect and impact of PMTCT
Measuring and modelling the impact of the HIV epidemic
Mechanisms of T cell depletion and dysfunction
Methodological Issues and Capacity-Building in Epidemiology and Prevention Research
Microbicides
Monitoring and evaluation (other)
Monitoring and evaluation of HIV prevention, care and treatment
Mother to child transmission
Mucosal immunity/defenses: responses and dysfunction
Mucosal transmission
Mycobacteria and TB
Natural history, progression and survival
Neurologic and psychiatric manifestations, including neurocognitive disorders
New HIV testing and diagnostic strategies
New monitoring strategies including rapid tests
Non pathogenic models of SIV
Non-AIDS related co-morbidities (e.g. diabetes, hypertension etc)
Non-AIDS related malignancies
Novel animal models for vaccine and inhibitor development
Novel assays of immune responses
Novel Treatment and Prevention Strategies
Novel vectors and strategies
Nucleic acid based HIV and SIV therapies
Opportunistic infections (excluding mycobacterial)
Other adverse reactions and complications of ARV therapy
Other bacterial infections and malaria and parasitic infections
Other complications
Other Therapies
Paediatric surveillance of HIV
Pharmacogenomics
Pharmacology, pharmacokinetics, drug formulations
Population-based surveys with HIV testing
Preclinical development of microbicides
Pre-exposure and post-exposure prophylaxis
Prevention addressing gender inequalities
Prevention for men who have sex with men (MSM)
Prevention for people living with HIV
Prevention for people who use drugs
Prevention for the general population
Prevention in institutional settings e.g. workplace, school, prison, military
Prevention of mother-to-child transmission
Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis and HPV, co-trimoxazole prophylaxis and IPT
Research designs in epidemiology
Sexually transmitted infections (STI)
Simplification strategies (induction/maintenance and use of bPI monotherapy)
STI prevention and control
Surveillance of HIV (Youth and Adults)
Surveillance systems and methods
Switch studies
Therapy for the heavily pre-treated patient
Track B - Clinical Sciences
Track C: Epidemiology and Prevention Sciences
Transmission and Early Infection
Tuberculosis
Viral determinants of SIV pathogenesis
Viral fitness and tropism assays, utility and application in clinical practice
Viral resistance testing in clinical trials and practice
Virus-specific cellular immunity
When to start therapy
Late breakers only
Track
Abstract codes
Abstract Categories
A
A001 - 009
HIV diversity and epidemiology
A
A010 - 012
HIV superinfections
A
A013
Bioinformatics analysis of viral diversity in natural history
A
A014
Bioinformatic analysis in drug resistance
A
A015 - 016
HIV Pathogenesis/Immune Function and Dysfunction
A
A017
Innate immunity responses and function in natural history of HIV infection
A
A018
Virus-specific cellular immunity
A
A019 - 022
Mucosal immunity/defenses: responses and dysfunction
A
A023 - 027
Correlates of immune protection
A
A028
Mechanisms of T cell depletion and dysfunction
A
A029
HIV Pathogenesis/Latency and Viral Reservoirs
A
A030 - 031
HIV tropism, dynamics and fitness
A
A032 - 034
Host genetics of resistance and susceptibility
A
A036 - 040
Transmission and Early Infection
A
A041
Animal models of transmission, disease resistance and progression
A
A042 - 044
Mucosal transmission
A
A045 - 046
Mother to child transmission
A
A047
Novel Treatment and Prevention Strategies
A
A048
Preclinical development of microbicides
A
A049 - 060
Nucleic acid based HIV and SIV therapies
A
A061 - 062
Antibody based vaccines
A
A063 - 066
Cellular immunity based vaccines
A
A067 - 073
Novel vectors and strategies
A
A074 - 077
Animal Models
A
A078
Viral determinants of SIV pathogenesis
A
A079 - 080
Non pathogenic models of SIV
A
A081
Novel animal models for vaccine and inhibitor development
A
A082
HIV-1 and HIV-2 co-infections
A
A083 - 084
Mycobacteria and TB
A
A085 - 090
Malaria
A
A091 - 096
Diagnostic Tools for the Immunological and Virological Monitoring of HIV Infection
A
A097 - 105
Novel assays of immune responses
A
A106 - 113
Track B - Clinical Sciences
B
B001 - 002
Acute and early infection
B
B003 - 004
Disease burden – morbidity/mortality
B
B005 - 008
Ageing
B
B009
Non-AIDS related co-morbidities (e.g. diabetes, hypertension etc)
B
B010 - 012
Impact of nutrition
B
B013 - 016
HIV-2
B
B017 - 019
New monitoring strategies including rapid tests
B
B020 - 029
Viral resistance testing in clinical trials and practice
B
B030
Viral fitness and tropism assays, utility and application in clinical practice
B
B031 - 036
Opportunistic infections (excluding mycobacterial)
B
B037 - 042
Tuberculosis
B
B043
Other bacterial infections and malaria and parasitic infections
B
B044 - 052
Hepatitis co-infections: (including HBV, HCV)
B
B053 - 057
Sexually transmitted infections (STI)
B
B058 - 059
Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis and HPV, co-trimoxazole prophylaxis and IPT
B
B060 - 061
Neurologic and psychiatric manifestations, including neurocognitive disorders
B
B062 - 064
Immune reconstitution disorders / IRIS
B
B065 - 067
AIDS related malignancies (KS, lymphoma, cervical and anal carcinoma) including HHV8 infection
B
B068 - 069
Non-AIDS related malignancies
B
B070 - 073
Clinical trials
B
B074 - 075
Cohort studies
B
B076
Acute and early infection and management of patients with acquired viral resistance
B
B077 - 078
Pharmacogenomics
B
B079 - 085
When to start therapy
B
B086 - 114
First line therapy
B
B088 - 123
Simplification strategies (induction/maintenance and use of bPI monotherapy)
B
B094 - 128
Switch studies
B
B095 - 096
Therapy for the heavily pre-treated patient
B
B097 - 100
Antiretroviral Therapies (strategic categories apply to resource rich and constrained settings) in Children and Adolescents
B
B101
Diagnosis of HIV disease
B
B102 - 105
Pharmacology, pharmacokinetics, drug formulations
B
B106 - 109
Antiretroviral therapy,clinical trials and cohorts
B
B115 - 118
Management of late presenters
B
B129
Complications of Anti-Retroviral Therapy and Adherence in Adults and Children
C
C001 - 004
Other adverse reactions and complications of ARV therapy
C
C005 - 024
Adherence in adults
C
C025 - 027
Adherence in children and adolescents
C
C028 - 030
Other complications
C
C031 - 036
Other Therapies
C
C037
Complementary and traditional medicines and the role of traditional healers in therapy
C
C038 - 039
Track C: Epidemiology and Prevention Sciences
C
C040 - 041
Natural history, progression and survival
C
C042
Epidemiology of HIV in people who use drugs
C
C043 - 047
Epidemiology of sexually transmitted infections (STI) and HIV
C
C048 - 049
Methodological Issues and Capacity-Building in Epidemiology and Prevention Research
C
C050 - 056
Research designs in epidemiology
C
C057 - 058
Ethical issues in epidemiological research
C
C059 - 060
Measuring and modelling the impact of the HIV epidemic
C
C061 - 063
Measuring and modelling the effect and impact of PMTCT
C
C064 - 068
Measuring and modelling the effect and impact of other HIV prevention interventions
C
C069 - 074
New HIV testing and diagnostic strategies
C
C075 - 078
Estimating the size of HIV-infected and most at risk population
C
C079 - 090
Estimating the need for HIV treatment
C
C091 - 094
HIV Surveillance, Monitoring and Evaluation
C
C095 - 099
Paediatric surveillance of HIV
C
C100 - 103
Surveillance of HIV (Youth and Adults)
C
C104 - 119
Behavioural surveillance
D
D001 - 015
Surveillance systems and methods
D
D016 - 019
Population-based surveys with HIV testing
D
D020 - 030
Monitoring and evaluation of HIV prevention, care and treatment
D
D031 - 049
Monitoring and evaluation (other)
D
D050 - 184
Prevention of mother-to-child transmission
D
D074 - 094
Male and female condoms and other physical barriers
D
D095 - 104
Harm reduction, including reduction of unsafe injecting and other approaches
D
D105 - 115
Blood, organ and tissue safety and nosocomial transmission
D
D116 - 122
Male circumcision
D
D123 - 133
STI prevention and control
D
D134 - 135
Pre-exposure and post-exposure prophylaxis
D
D136
Microbicides
D
D137 - 138
Antiretroviral treatment of people living with HIV for prevention
D
D139
Approaches to counselling and testing in children and caregivers
D
D140 - 147
HIV counselling, testing and diagnostic strategies
D
D148 - 159
Prevention in institutional settings e.g. workplace, school, prison, military
D
D160
Prevention for the general population
D
D161
Prevention addressing gender inequalities
D
D162 - 166
Prevention for people who use drugs
D
D167 - 185
Prevention for men who have sex with men (MSM)
D
D174 - 183
Prevention for people living with HIV
Back to the Programme-at-a-Glance
Contact Us
|
Site map
© 2009 International AIDS Society